Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine cardiovascular risk and inflammatory marker study in rheumatoid arthritis and systemic lupus erythematosus
2014-005418-45Phase 2Completed
- Sponsor
- Christine Bengtsson
- Start
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of hydroxychloroquine in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) (2 arms), sponsored by Christine Bengtsson. Primary endpoint: Blood lipid profile. Started Mar 2015; status: completed.
02
Drugs
hydroxychloroquine
03
Conditions
rheumatoid arthritis (RA)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2014-005418-45.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005418-45.